It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.
ImmuPharma PLC CEO Dimitri Dimitriou had an excellent day on 28 November as his daughter got married and the UK biotech signed a deal for Lupuzor with the US's Avion Pharmaceuticals LLC that has breathed new life into the prospects for the investigational lupus drug.
The pact will see Avion pay for a new Phase III trial up to $25m for Lupuzor (forigerimod), ImmuPharma's first-in...
MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.
The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.
More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
